Given their pivotal role in cell cycle regulation and cancer, cyclins are considered potential targets for cancer therapy. CDK inhibitors, such as Palbociclib, Ribociclib, and Abemaciclib, have been developed to inhibit the activity of cyclin-CDK complexes. These inhibitors have shown promise in treating cancers like breast cancer by inducing cell cycle arrest and reducing tumor growth.
